☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Duloxetine Update

Duloxetine (Cymbalta®) is an antidepressant that has been the subject of several previous postings. Some of this information is now in need of an update.

To clarify the current situation:

  • The Scottish Medicines Consortium have restricted use of duloxetine in Scotland
  • Lancashire Care Trust have restrictions in place on duloxetine
  • The Summary of Product Characteristics recommends that patients (and carers) are made aware of the need to monitor for suicidal ideation/behaviour and that there is "close supervision of high-risk patients"
  • The MHRA publication Current Problems in Pharmacovigilance recommends "careful and frequent patient monitoring during treatment is recommended, particularly for high risk groups."
  • [Update] Leeds NHS Health Community (PCT, Acute and Care Trusts) have recommended restricted use of duloxetine

Action: The existing advice remains unchanged at this time; duloxetine should not be used as an antidepressant in a Primary Care Setting.

Share 'Duloxetine Update' by emailShare 'Duloxetine Update' on FacebookShare 'Duloxetine Update' on TwitterShare 'Duloxetine Update' on MastodonShare 'Duloxetine Update' on LinkedInShare 'Duloxetine Update' on reddit

atomic-wealth

No Comments to “Duloxetine Update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.